ATE545655T1 - Fgfr-bindende peptide - Google Patents

Fgfr-bindende peptide

Info

Publication number
ATE545655T1
ATE545655T1 AT05748535T AT05748535T ATE545655T1 AT E545655 T1 ATE545655 T1 AT E545655T1 AT 05748535 T AT05748535 T AT 05748535T AT 05748535 T AT05748535 T AT 05748535T AT E545655 T1 ATE545655 T1 AT E545655T1
Authority
AT
Austria
Prior art keywords
compounds
fgfr
ncam
peptide sequences
peptide
Prior art date
Application number
AT05748535T
Other languages
English (en)
Inventor
Eisabeth Bock
Vladimir Berezin
Original Assignee
Enkam Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As
Application granted granted Critical
Publication of ATE545655T1 publication Critical patent/ATE545655T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05748535T 2004-06-18 2005-06-17 Fgfr-bindende peptide ATE545655T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400963 2004-06-18
PCT/DK2005/000400 WO2005123759A2 (en) 2004-06-18 2005-06-17 Fgfr binding peptides

Publications (1)

Publication Number Publication Date
ATE545655T1 true ATE545655T1 (de) 2012-03-15

Family

ID=35510321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05748535T ATE545655T1 (de) 2004-06-18 2005-06-17 Fgfr-bindende peptide

Country Status (11)

Country Link
US (1) US20090074774A1 (de)
EP (1) EP1765861B1 (de)
JP (1) JP2008504236A (de)
CN (1) CN101027320A (de)
AT (1) ATE545655T1 (de)
AU (1) AU2005254613A1 (de)
BR (1) BRPI0512254A (de)
CA (1) CA2570267A1 (de)
MX (1) MXPA06014804A (de)
WO (1) WO2005123759A2 (de)
ZA (1) ZA200610546B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540644A1 (en) * 2003-09-30 2005-04-07 Enkam Pharmaceuticals A/S A method of modulating cell survival, differentiation and/or synaptic plasticity
US8618060B2 (en) 2006-02-14 2013-12-31 University Of Tasmania Metallothionein-derived peptide fragments
WO2007110079A2 (en) * 2006-03-29 2007-10-04 Enkam Pharmaceuticals A/S Targeted delivery of fgfr ligands into the brain
CN101619093B (zh) * 2009-05-26 2011-12-07 中国人民解放军第三军医大学野战外科研究所 具有促进成纤维细胞生长因子受体3活性的多肽及其筛选方法和应用
US20120315244A1 (en) 2009-09-30 2012-12-13 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Inhibiting Gene Products
AU2013271609A1 (en) 2012-06-05 2014-12-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using NCAM peptide mimetics
CN109867724B (zh) * 2019-04-19 2020-09-15 温州医科大学 一种fgfr抗体及其在脊髓损伤治疗中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4599311A (en) * 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5693488A (en) * 1994-05-12 1997-12-02 The Rockefeller University Transmembrane tyrosine phosphatase, nucleic acids encoding the same, and methods of use thereof
US20020104122A1 (en) * 1994-06-17 2002-08-01 Kirin Beer Kabushiki Kaisha Methods for producing a plant with enhanced resistance to pathogenic fungi
WO2001031019A2 (en) * 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
GB0014870D0 (en) * 2000-06-16 2000-08-09 King S College London Peptides
JP4402455B2 (ja) * 2001-08-17 2010-01-20 エンカム ファーマシューティカルズ アクティーゼルスカブ 細胞の分化、増殖、再生、可塑性及び生存に影響を及ぼすことができる化合物
DE602004030824D1 (de) * 2003-11-21 2011-02-10 Ace Biosciences As An der oberfläche befindliche campylobacter jejuni-polypeptide

Also Published As

Publication number Publication date
US20090074774A1 (en) 2009-03-19
JP2008504236A (ja) 2008-02-14
WO2005123759A3 (en) 2006-05-04
BRPI0512254A (pt) 2008-02-19
AU2005254613A1 (en) 2005-12-29
ZA200610546B (en) 2008-06-25
EP1765861B1 (de) 2012-02-15
CN101027320A (zh) 2007-08-29
WO2005123759A8 (en) 2006-03-09
MXPA06014804A (es) 2007-03-23
WO2005123759A2 (en) 2005-12-29
CA2570267A1 (en) 2005-12-29
EP1765861A2 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
ZA200610546B (en) FGFR binding peptides
WO2007051477A3 (en) Neurotrophin-derived peptide sequences
WO2006119767A3 (en) Neuritogenic peptides
WO2006125227A3 (en) Fibroblast activation protein inhibitor compounds and methods
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
ATE472327T1 (de) Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
WO2005123048A3 (en) Screening methods using c-abl, fyn and syk in combination with tau protein
ATE469921T1 (de) Lpa-haltige verbindungen
NO20052222L (no) Farmasoytisk preparat omfattende krystallinsk sibutraminmetansulfonathemihydrat
ATE458746T1 (de) Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
WO2007074456A3 (en) Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids
WO2000018801A3 (en) Ncam binding compounds
Sharma et al. tert-Butyl 1, 5-bis (4-(benzo [d] isothiazol-3-yl) piperazin-1-yl)-1, 5-dioxopentan-2-ylcarbamate urea/thiourea derivatives as potent H+/K+-ATPase inhibitors
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
ATE552273T1 (de) Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
WO2005118920A3 (en) Methods for generating neuronal cells from human embryonic stem cells and uses thereof
JP2008508363A5 (de)
WO2009068042A3 (en) Novel peptides derived from ncam (fgls)
WO2007071248A8 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
WO2007045243A3 (en) Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
WO2005025514A3 (en) Compounds that modulate neuronal growth and their uses
ATE531384T1 (de) Peptide aus dem plasminogenaktivator-hemmer 1 und ihre verwendung
IL176898A0 (en) Growth factor-binding compounds and methods of use
WO2005121168A3 (en) Heparin binding peptide